Bionano Genomics raises FY26 sales guidance range
Bionano Genomics Inc. upgrades FY2026 sales guidance to $31.000M-$33.000M, up from $30.000M-$33.000M. The new outlook beats the $32.137M consensus estimate, indicating improved revenue visibility and reduced downside risk for the fiscal year.
*this image is generated using AI for illustrative purposes only.
Bionano Genomics Inc. (NASDAQ: BNGO) has raised its sales guidance for the fiscal year ending in 2026, signaling stronger-than-expected demand for its genomics solutions. The company increased the lower end of its revenue forecast by $1.000 million, setting a new range of $31.000 million to $33.000 million. This adjustment places the midpoint of the company’s outlook above the consensus analyst estimate of $32.137 million, reflecting improved operational visibility for the remainder of the fiscal period.
The revision narrows the gap between the company’s internal projections and external market expectations. By lifting the floor of its guidance, Bionano Genomics demonstrates confidence in its near-term revenue generation capabilities. The upper bound of the forecast remains unchanged at $33.000 million, indicating that while downside risk has been mitigated, the ceiling for growth remains consistent with prior assessments.
Guidance Revision Details
The following table outlines the changes to Bionano Genomics’ FY2026 sales outlook:
| Metric | Previous Guidance | Revised Guidance | Market Estimate |
|---|---|---|---|
| Lower Bound | $30.000 million | $31.000 million | - |
| Upper Bound | $33.000 million | $33.000 million | - |
| Midpoint | $31.500 million | $32.000 million | $32.137 million |
What the Numbers Show
The upward revision of the lower bound suggests that Bionano Genomics has secured sufficient order flow or commercial traction to de-risk its annual target. The fact that the revised midpoint ($32.000 million) is only marginally below the consensus estimate ($32.137 million) implies that the company is positioning itself to meet or potentially exceed analyst expectations. Investors should monitor subsequent quarterly reports to determine whether this guidance adjustment reflects a structural shift in revenue drivers or a temporary acceleration in bookings.
Which specific customer segments or geographic regions are driving the stronger-than-expected demand that prompted this guidance increase?
How does Bionano Genomics plan to sustain revenue growth beyond FY2026 given that the upper bound of the forecast remains unchanged?
What is the current backlog status, and does the revised guidance reflect a one-time surge in bookings or a recurring trend in order flow?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
